1 Min Read
July 25 (Reuters) - Helix Biopharma Corp
* Helix Biopharma Corp. initiates enrollment in the third dosing cohort of U.S. combination treatment study of its lung cancer drug candidate l-DOS47 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.